NEWS

Spahn/Karliczek: Weiterer Schub zur Entwicklung und Herstellung von versorgungsnahen Arzneimitteln gegen COVID-19

Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin

Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente

Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

LightOx May 2020

Xenikos receives FDA Fast Track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease

Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD

Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard(R) in acute graft-versus-host disease

Xenikos announces data from phase I/II trial with T-Guard™ for treatment of steroid-resistant acute GVHD presented at ASH Annual Meeting